HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab
Pathology and Oncology Research · 2025
DOI: 10.3389/pore.2025.1611999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology and Oncology Research, 2025. Verfasst von Toàn Minh Ngô und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Radiopharmaceuticals, Melanoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Positron emission tomography (PET) hybrid imaging targeting HER2 requires antibodies labelled with longer half-life isotopes. With a suitable radiation profile, 52 Mn coupled with DOTAGA as a bifunctional chelator is a potential candidate. In this study, we investigated the tumor HER2 specificity and the temporal biodistribution of the [ 52 Mn]Mn-DOTAGA(anhydride)-trastuzumab in preclinical models.
Methods
PET/MRI and PET/CT were performed on SCID mice bearing orthotopic and ectopic HER2-positive and ectopic HER2-negative tumors at 4, 24, 48, 72, and 120 h post-injection with [ 52 Mn]Mn-DOTAGA(anhydride)-trastuzumab. Melanoma xenografts were included for comparison of specificity.
Results
In vivo biodistribution demonstrated strong contrast in HER2-positive tumors, particularly in orthotopic tumors, where uptake was significantly higher than in the blood pool and other organs from 24 h onwards and consistently higher than in ectopic HER2-positive tumors at all time points. Significantly higher tumor-to-blood and tumor-to-muscle ratios were observed in HER2-positive ectopic tumors compared to HER2-negative tumors but only at 4 and 24 h; the differences were likely due to non-specific binding of the tracer. The ratios for orthotopic HER2-positive tumors were significantly higher than those for ectopic HER2-negative tumors and melanoma at all time points. However, the differences between HER2-positive and HER2-negative tumors decreased at later time points.
Conclusion
These results suggest that [ 52 Mn]Mn-DOTAGA(anhydride)-trastuzumab demonstrates efficient tumor-to-background contrast, emphasize the higher tumor uptake observed in orthotopic tumors, and highlight the influence of tumor environment characteristics on uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Department of Nuclear Medicine, Medical Imaging Clinic, Clinical Centre, University of Debrecen, Debrecen, Hungary.
- Scanomed Ltd., Debrecen, Hungary.
- Department of Physical Chemistry, Institute of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, Hungary.
Zitieren
APA
Ngô, T. M., Vágner, A., Nagy, G., Ország, G., Nagy, T., Szoboszlai, Z., Csikos, C., Váradi, B., Trencsényi, G., Tircsó, G., & Garai, I. (2025). HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab. Pathology and Oncology Research. https://doi.org/10.3389/pore.2025.1611999
Vancouver
Ngô TM, Vágner A, Nagy G, Ország G, Nagy T, Szoboszlai Z, et al. HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab. Pathology and Oncology Research. 2025. doi:10.3389/pore.2025.1611999
BibTeX
@article{Ng2025,
author = {Ngô, Toàn Minh and Vágner, Adrienn and Nagy, Gábor and Ország, Gábor and Nagy, Tamás and Szoboszlai, Zoltán and Csikos, Csaba and Váradi, Balázs and Trencsényi, György and Tircsó, Gyula and Garai, Ildikó},
title = {HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab},
journal = {Pathology and Oncology Research},
year = {2025},
doi = {10.3389/pore.2025.1611999}
}
EUVIMED